Physician profile
Frederick U Goss
NPI 1447236070
$1,709.55
in general payments reported to CMS, 2019-2025
26 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $130 · 2021: $132 · 2022: $12.39 · 2023: $321 · 2024: $206 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $199.59 | 2019-2021 | |
| Astellas Pharma US INC | $149.51 | 2019-2023 | Veozah |
| Genentech USA, INC. | $140.98 | 2019-2023 | Actemra |
| Boston Scientific Corporation | $129.70 | 2025 | Watchman Flx |
| Gilead Sciences, INC. | $109.08 | 2025 | Epclusa |
| Inspire Medical Systems, INC. | $107.44 | 2024 | Inspire |
| Daiichi Sankyo INC. | $92.95 | 2019-2023 | Injectafer |
| Dexcom, INC. | $87.72 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $75.96 | 2019-2024 | |
| Glaxosmithkline, LLC. | $70.33 | 2019 | |
| Lilly USA, LLC | $68.72 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $66.88 | 2019-2021 | |
| Abbott Laboratories | $48.38 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $43.53 | 2024-2025 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $42.10 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.81 | 2019 | |
| Abbvie INC. | $35.62 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.10 | 2023 | |
| Organon LLC | $30.22 | 2023 | Hadlima |
| Horizon Therapeutics Plc | $27.18 | 2020-2023 | Krystexxa |
| Electromed, INC. | $23.95 | 2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $23.79 | 2019-2022 | |
| Baxter Healthcare | $23.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.69 | 2019 | |
| Masimo Corporation | $15.41 | 2021 | |
| Fidia Pharma USA INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Goss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.